微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 73.9% | 1.85% | 1.28% | 28/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 72.96% | 1.41% | 3.81% | 30/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 70.29% | 2.2% | -1.64% | 29/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 71.46% | 0.63% | -1.51% | 30/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 72.56% | 2.14% | 0.84% | 28/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 71.95% | 0.94% | 4.62% | 31/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 68.78% | -5.54% | -3.16% | 32/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 71.02% | 2.16% | -0.02% | 33/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 71.03% | 4.65% | -0.35% | 32/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 71.28% | 3.41% | -2.1% | 34/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 72.81% | 4.43% | 4.74% | 32/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 69.51% | 5.35% | 2.41% | 39/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 67.87% | 6.71% | -1.53% | 44/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 68.93% | 7% | -1.13% | 44/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 69.72% | 0.7% | 5.66% | 39/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 65.98% | -3.06% | 3.73% | 51/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 63.61% | -9.37% | -1.26% | 49/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 64.42% | -8.4% | -6.95% | 49/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 69.23% | 0.22% | 1.71% | 32/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 68.07% | 3.51% | -3.02% | 44/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 70.18% | 9.78% | -0.21% | 33/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 70.33% | 11.13% | 1.81% | 32/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 69.08% | 14.99% | 5.05% | 27/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 65.76% | 16.3% | 2.86% | 43/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 63.93% | 0.16% | 1.02% | 38/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 63.29% | 0.98% | 5.35% | 42/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 60.07% | -8.34% | 6.25% | 40/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 56.54% | -12.42% | -11.42% | 64/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 63.83% | -8.66% | 1.85% | 30/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 62.67% | -22.12% | -4.38% | 36/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 65.54% | -16.91% | 1.52% | 29/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 64.56% | -12.95% | -7.62% | 34/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 69.88% | -2.48% | -13.15% | 17/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 80.47% | 13.08% | 2.01% | 6/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 78.88% | 14.5% | 6.36% | 7/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 74.17% | 10.6% | 3.5% | 16/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 71.66% | 5.04% | 0.7% | 11/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 71.16% | 3.7% | 3.3% | 12/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 68.89% | -3.94% | 2.73% | 11/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 67.06% | -3.83% | -1.71% | 17/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 68.22% | -4.76% | -0.58% | 12/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 68.62% | -3.34% | -4.31% | 13/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 71.71% | 4.21% | 2.84% | 11/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |